CSPC Group announced that SYS6010, developed by the Group, was recently added to the list of breakthrough treatment varieties by the State Drug Administration. The proposed indications are recurrent or metastatic head and neck squamous cancer that has previously failed to be treated with immunization and platinum-containing chemotherapy.

CSPC Group announced that SYS6010, developed by the Group, was recently added to the list of breakthrough treatment varieties by the State Drug Administration. The proposed indications are recurrent or metastatic head and neck squamous cancer that has previously failed to be treated with immunization and platinum-containing chemotherapy.